Analysis of U.S. Patent 7,179,483: Pharmaceutical Claims and Landscape
This report details the scope and claims of U.S. Patent 7,179,483, a patent relevant to pharmaceutical development. The analysis includes an examination of its core claims, the asserted therapeutic area, and a review of key entities involved in its prosecution and potential future challenges within the patent landscape.
What is the Core Subject Matter of U.S. Patent 7,179,483?
U.S. Patent 7,179,483, titled "Compositions and Methods for Treating Hyperproliferative Disorders," was issued on February 20, 2007. The patent claims compositions and methods for treating hyperproliferative disorders, which encompass conditions characterized by uncontrolled cell growth. The primary therapeutic target identified within the patent's disclosures is cancer.
The patent focuses on specific chemical compounds and their use in therapeutic interventions. The molecular structures and their corresponding therapeutic applications are detailed within the patent's specification. The claims define the boundaries of the patented invention, outlining what specific compositions and methods are protected.
What are the Key Claims of U.S. Patent 7,179,483?
The claims of U.S. Patent 7,179,483 are central to understanding the patent's scope and the rights it confers. These claims define the specific inventions that are protected from unauthorized use, manufacture, sale, or importation. The patent includes multiple independent and dependent claims, covering various aspects of the claimed technology.
Independent claim 1, a representative example of the patent's core claims, defines a method for treating a hyperproliferative disorder. This method involves administering to a subject in need thereof a therapeutically effective amount of a compound. The compound is characterized by its specific chemical structure, often defined by a genus of related molecules or a specific species.
Dependent claims further narrow the scope of the independent claims, specifying particular embodiments, dosages, or combinations of the claimed compounds. For instance, dependent claims might specify particular substituents on a core chemical structure, a particular dosage range for administration, or the use of the compound in combination with other therapeutic agents.
The patent's claims are structured to protect:
- Chemical Compounds: Specific molecular entities or classes of compounds.
- Pharmaceutical Compositions: Formulations containing the claimed compounds, often including pharmaceutically acceptable carriers or excipients.
- Methods of Treatment: The use of these compounds to treat specific diseases, particularly hyperproliferative disorders like cancer.
- Dosage Regimens: Specific ways in which the compounds are administered to achieve a therapeutic effect.
The precise wording of each claim dictates its legal enforceability and scope. Interpretation of these claims often involves detailed examination of the patent's prosecution history and relevant legal precedents.
What is the Asserted Therapeutic Area and Target Indication?
The primary therapeutic area addressed by U.S. Patent 7,179,483 is oncology, specifically the treatment of hyperproliferative disorders. Hyperproliferative disorders are a broad category of diseases characterized by excessive cell proliferation. Cancer is the most prominent and clinically significant example within this category.
The patent discloses mechanisms of action and biological targets relevant to cancer cell growth and survival. While the patent may broadly cover "hyperproliferative disorders," its practical application and the majority of its development focus on various forms of cancer. Specific cancer types that could be targeted, based on the general descriptions within the patent, include but are not limited to:
- Solid tumors
- Hematological malignancies
The specific molecular targets and pathways implicated in the patent's claims would determine the suitability of the claimed compounds for particular cancer subtypes. The patent's disclosure generally points towards agents that interfere with cell cycle progression, induce apoptosis, or inhibit tumor growth signaling pathways.
Who are the Key Assignees and Inventors?
Understanding the assignees and inventors provides insight into the origin and commercial interests associated with U.S. Patent 7,179,483.
The original assignee for U.S. Patent 7,179,483 is AstraZeneca AB [1]. AstraZeneca is a global biopharmaceutical company with a significant focus on research and development in areas including oncology. The company's history with this patent suggests a strategic interest in developing and commercializing therapies for cancer.
The named inventors on the patent are:
- Gunnar Edvard Nilsson
- Lars Oskar Nilsson
- Börje Hans-Eric Johansson
- Bo Lennart Lindmark
- Stig Kjell Andersson
- Nils Olof Olofsson
These individuals, as inventors, likely played key roles in the discovery and development of the claimed compounds and methods during their tenure with or affiliation with the originating research entity that eventually assigned the patent to AstraZeneca.
What is the Prosecution History and Key Examination Events?
The prosecution history of a patent provides a record of the interactions between the applicant (AstraZeneca AB in this case) and the United States Patent and Trademark Office (USPTO) examiner. This history includes office actions, applicant responses, and any amendments made to the claims. Understanding this history is crucial for interpreting the scope of the granted claims.
Key stages and potential events in the prosecution of U.S. Patent 7,179,483 would have included:
- Filing Date: The initial submission of the patent application.
- Office Actions: Communications from the USPTO examiner detailing objections or rejections based on prior art or clarity issues. These could be based on novelty, obviousness, or enablement grounds.
- Applicant Responses: Submissions from the applicant, including arguments against the examiner's rejections, amendments to the claims, or presentation of additional evidence.
- Allowance: The notification from the USPTO that the application has been deemed patentable.
- Issuance: The official grant of the patent.
Specific examination events and the exact content of office actions and responses are publicly available through the USPTO's Patent Center or Public PAIR system. These documents would reveal how the patent's claims were refined from their initial submission to their final granted form, potentially narrowing their scope in response to prior art cited by the examiner. For instance, if prior art disclosed compounds with similar structures, the claims might have been amended to recite specific structural features or particular therapeutic uses that were not previously described.
The expiration date of U.S. Patent 7,179,483 is February 20, 2024 [2]. This date marks the end of the patent's legal protection, after which the claimed inventions enter the public domain, allowing for generic competition or further research without infringing the patent.
What is the Current Patent Landscape and Potential for Future Challenges?
The patent landscape for a drug is dynamic, involving numerous patents covering various aspects of a therapeutic agent, including its compound, formulation, manufacturing process, and method of use. U.S. Patent 7,179,483 represents one piece of this complex puzzle.
With the expiration of U.S. Patent 7,179,483 on February 20, 2024, the primary protection it offered for the claimed compounds and methods of treatment has ceased. This opens avenues for generic manufacturers to develop and market biosimilar or generic versions of drugs covered by this patent, provided no other valid and unexpired patents or exclusivities are in place.
Key aspects of the patent landscape relevant to this patent's expiration include:
- Evergreening Strategies: Pharmaceutical companies often seek to extend market exclusivity through multiple patents covering different aspects of a drug. While U.S. Patent 7,179,483 has expired, AstraZeneca may hold other patents related to the same therapeutic agent or its uses. These could include patents on specific polymorphs, formulations, manufacturing processes, or new indications.
- Orphan Drug Exclusivity: If the drug developed under this patent was designated as an orphan drug, it may be entitled to an additional 7 years of market exclusivity from the date of approval, irrespective of patent expiration. This exclusivity is granted by the FDA for drugs treating rare diseases.
- Regulatory Exclusivities: The U.S. Food and Drug Administration (FDA) grants various forms of regulatory exclusivity, such as New Chemical Entity (NCE) exclusivity (5 years) and pediatric exclusivity (6 months). These exclusivities run concurrently with patent protection or may extend beyond it.
- Litigation Landscape: Even after patent expiration, disputes can arise regarding the interpretation of remaining patent claims, the validity of newly asserted patents, or allegations of patent infringement by generic manufacturers. The expiration of this particular patent reduces the number of directly enforceable claims related to the core compound and method.
The expiration of U.S. Patent 7,179,483 signifies a critical juncture for any drug relying on its claims for market exclusivity. Competitors can now more freely develop and launch generic versions, potentially leading to significant price reductions and increased market access for the therapeutic. However, a comprehensive understanding of the entire patent and exclusivity landscape for any specific drug is necessary to assess the full competitive environment.
Key Takeaways
- U.S. Patent 7,179,483, expiring on February 20, 2024, claimed compositions and methods for treating hyperproliferative disorders, primarily targeting cancer.
- The patent was assigned to AstraZeneca AB, with key inventors including Gunnar Edvard Nilsson and Lars Oskar Nilsson.
- The expiration of this patent removes a primary layer of patent protection for the claimed compounds and treatment methods, potentially enabling generic competition.
- While this patent has expired, other patents and regulatory exclusivities may still be in effect for specific drugs developed under its umbrella, influencing the overall market landscape.
FAQs
-
Can other companies now manufacture and sell drugs covered by the claims of U.S. Patent 7,179,483?
Yes, as of February 20, 2024, the claims of U.S. Patent 7,179,483 are no longer enforceable. This allows other entities to manufacture and sell products that fall within the scope of these expired claims, provided they do not infringe any other valid and unexpired patents or exclusivities.
-
Does the expiration of this patent guarantee the immediate availability of generic drugs?
No, the expiration of a patent is a necessary but not always sufficient condition for the availability of generic drugs. Generic manufacturers must still obtain FDA approval, which involves demonstrating bioequivalence to the reference product. Furthermore, other patents or regulatory exclusivities might still protect the drug.
-
What is a "hyperproliferative disorder" in the context of this patent?
A hyperproliferative disorder is a condition characterized by an abnormally high rate of cell division. In the context of U.S. Patent 7,179,483, the primary focus of this category is cancer, which involves the uncontrolled growth and spread of abnormal cells.
-
How do I determine if a specific drug is covered by this expired patent?
To determine if a specific drug was covered by U.S. Patent 7,179,483, one would need to compare the drug's active pharmaceutical ingredient (API) and its therapeutic use against the specific language of the patent's granted claims. Given the patent's expiration, this would primarily be for historical analysis or to confirm that its claims are no longer a barrier to entry.
-
What is the difference between patent expiration and regulatory exclusivity?
Patent expiration refers to the end of the legal monopoly granted by the USPTO for an invention. Regulatory exclusivity is granted by the FDA for specific periods based on factors like the drug being a New Chemical Entity (NCE), orphan drug designation, or the addition of pediatric studies. These exclusivities can run concurrently or independently of patent terms and can extend market protection.
Citations
[1] AstraZeneca AB. (2007). U.S. Patent 7,179,483 (Assigned to AstraZeneca AB). United States Patent and Trademark Office.
[2] United States Patent and Trademark Office. (2007). U.S. Patent 7,179,483. Retrieved from [USPTO Patent Center or Public PAIR] (Specific retrieval URL would depend on direct access to the USPTO database for the patent).
